COLOR III trial=Extensive Quality Assurance with Central review: Indication: 💿MRI Surgical technique: 📹Operation 🎞️ Pathology: 📷Specimen Local recurrence: MRI 💿3 years FU all 🔗linked to clinical outocme in online 🔐💻platform. #TaTME #TaTME_month #colorectalresearch

Exciting news! The COLOR3 trial has just reached a major milestone. We have successfully randomised 1000 patients! We would like to thank all participating centres for their great efforts. We hope to reach final enrolment in December or January 2024! Let's keep up the good work!

@SPerdawood yes, absolutely: the interim analysis showed no safety issues, so we were able to continu the trial! We will reach the full sample size in approximately 9 to 10 months 💪

@JohnRTMonsonMD thank you!

COLOR3 update📢: currently we have included 952 and randomized 874 patients! Thanks to all centers and their persistant effort in this high quality trial on #tatme and #laptme! Please keep on including patients to reach the full sample size of 1104 patients next year. 🙏

📈 Trial update: we have included 857 patients and randomized 786 patients! Top including centers are Beijing Friendship Hospital (China), National Cancer Center Hospital East (Japan) and Gelderse Vallei (Netherlands). A big thanks to all participating centers! #tatme #surgery

🏆Today our top 1 including center Friendship Hospital Beijing included their 100th COLOR patient! Congratulations and thank you for your fantastic work! Special thanks to @Hongweiyao #TaTME #rectalsurgery #color3china

RT @SPerdawood: “Surgeons with experience in TaTME are not advised against performing TaTME in patients with low rectal cancer …”. https://…

Please join us at the international COLOR III meeting on the 3rd of March 2022 at 13:00hr (Amsterdam Time) with our collaborators from all over the world! We will discuss the progress of the COLOR III trial and interesting topics regarding rectal surgery #TaTME #rectalsurgery

RT @PelvExGroup: Looking for to the 3rd PelvEx meeting in the beautiful city Amsterdam - See for details ⁦@PelvExGr…

📈Trial update 6.1.22 We have reached #700! Total registered 773, randomized 705. Top including centers of Dec = Friendship Hospital Beijing (8), Gelderse Vallei (3), NCCH-East Japan (3), FHA-Chongqing (3).The accrual of Dec = 23. Big🙏to all! #tatme @colinsietses @AntoniodeLacy

RT @BJSurgery: In November's issue of BJS: Comparison of laparoscopic versus robot-assisted versus transanal total mesorectal excision surg…

RT @RoelHompes: @SWexner @ParisTekkis @JNCCN @taTMEsurgery @taTME_education @TATMEtrainingUK @UStaTMEtrial @patsyllamd @SamAtallahMD @TAMIS…

🚨Accrual update 26 nov '21 Total patients registered 747 Randomized 680 Some excl by second read of MRI /M+ 👏Participating centres 🙏 for efforts so far, please keep including patients! #TaTME @EAES_eu #WCES2021 @AntoniodeLacy @colinsietses @FelixAigner2 @SvanOostendorp

📈Study update #TaTME: #649 randomized pts of the full sample size of #1104! Top 3 including centers: 1. Beijing Friendship Hospital China @yaohongwei, 2. Gelderse Vallei NL @colinsietses and Shanghai Renji Hospital China @QingXu. Big🙏to all collaborators for their great work

Today we will be presenting the COLOR III trial at the ESCP conference! #ESCP2021 Please join us! #tatme #rectum

Today the virtual 16th Annual Scientific Conference of the European Society of Colorproctology @escp_tweets starts. On Friday Sept 24th we will present the COLOR III trial at the 'New Trial Forum' (time: 8.30AM till 09.45AM) to invite even more centers to join the COLOR3 group!

RT @SvanOostendorp: Last Friday 2/7/‘21 - #PhD defense @amsterdamumc @VUamsterdam “Minimally invasive treatment strategies for rectal canc…

RT @SWexner: Congratulations Dr. @borjadelacy on your incredibly impressive defense today of your PhD thesis @UniBarcelona and the very wel…

RT @KnolJoep: Looking forward!